Payment overview · 2025
General Payments
$182.34
6 reported records · 6 companies
Healthcare provider profile · identity verified
Ray Thomas Townsend, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BLAIRSVILLE, GA · NPI 1184909897
Verified facts
What the public records show
CMS Open Payments records show Ray Thomas Townsend, PA-C received $182.34 in general payments during 2025 across 6 reported records.
Inspire Medical Systems, Inc. accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $100.05 | 54.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.00 | 9.9% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $17.76 | 9.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.05 | 9.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.76 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.72 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $182.34 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $100.05 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 538 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 110 |
| Lisinopril | Lisinopril | 400 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 96 |
| Losartan Potassium | Losartan Potassium | 387 | 108 |
| Potassium Chloride | Potassium Chloride | 352 | 95 |
| Gabapentin | Gabapentin | 344 | 83 |
| Prednisone | Prednisone | 307 | 171 |
| Tramadol Hcl | Tramadol Hcl | 277 | 66 |
| Azithromycin | Azithromycin | 261 | 169 |
| Metoprolol Tartrate | Metoprolol Tartrate | 257 | 62 |
| Montelukast Sodium | Montelukast Sodium | 257 | 63 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 256 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 183 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 43 |
| Famotidine | Famotidine | 157 | 42 |
| Omeprazole | Omeprazole | 155 | 45 |
| Trazodone Hcl | Trazodone Hcl | 154 | 35 |
| Metformin Hcl | Metformin Hcl | 153 | 45 |
| Farxiga | Dapagliflozin Propanediol | 144 | 31 |
| Sertraline Hcl | Sertraline Hcl | 144 | 26 |
| Buspirone Hcl | Buspirone Hcl | 138 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 134 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 126 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 51 |
| Celecoxib | Celecoxib | 119 | 21 |
| Diazepam | Diazepam | 119 | 18 |
| Furosemide | Furosemide | 117 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 114 | 41 |
| Meloxicam | Meloxicam | 109 | 24 |
| Methocarbamol | Methocarbamol | 109 | 44 |
| Promethazine Hcl | Promethazine Hcl | 106 | 16 |
| Clonazepam | Clonazepam | 105 | 12 |
| Lorazepam | Lorazepam | 102 | 18 |
| Jardiance | Empagliflozin | 99 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 25 |
| Ibuprofen | Ibuprofen | 98 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 24 |
| Mounjaro | Tirzepatide | 91 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 25 |
| Glimepiride | Glimepiride | 86 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 20 |
| Alendronate Sodium | Alendronate Sodium | 83 | 18 |
| Simvastatin | Simvastatin | 79 | 18 |
| Januvia | Sitagliptin Phosphate | 78 | 14 |
| Carvedilol | Carvedilol | 71 | 20 |
| Methylprednisolone | Methylprednisolone | 70 | 58 |
| Cefdinir | Cefdinir | 69 | 52 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 46 |
| Vraylar | Cariprazine Hcl | 69 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 15 |
| Torsemide | Torsemide | 67 | 21 |
| Spironolactone | Spironolactone | 65 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 46 |
| Eliquis | Apixaban | 62 | 18 |
| Trulicity | Dulaglutide | 62 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 20 |
| Topiramate | Topiramate | 61 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 15 |
| Allopurinol | Allopurinol | 60 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 42 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 46 |
| Synthroid | Levothyroxine Sodium | 58 | 14 |
| Fluconazole | Fluconazole | 57 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 31 |
| Ezetimibe | Ezetimibe | 50 | 15 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 11 |
| Amoxicillin | Amoxicillin | 47 | 26 |
| Mupirocin | Mupirocin | 47 | 27 |
| Sucralfate | Sucralfate | 47 | 11 |
| Temazepam | Temazepam | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Finasteride | Finasteride | 42 | 11 |
| Linzess | Linaclotide | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 16 |
| Atenolol | Atenolol | 40 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 11 |
| Colestipol Hcl | Colestipol Hcl | 38 | 13 |
| Baclofen | Baclofen | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | 12 |
| Naproxen | Naproxen | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Nystatin | Nystatin | 32 | 21 |
| Cephalexin | Cephalexin | 30 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 20 |
| Levofloxacin | Levofloxacin | 28 | 18 |
| Ozempic | Semaglutide | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 25 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Buprenorphine | Buprenorphine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Qulipta | Atogepant | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Metronidazole | Metronidazole | 14 | 12 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $182.34 · 6 records | Inspire Medical Systems, Inc. | CAPLYTA, Cologuard Collection Kit, FANAPT, INSPIRE, TANLOR, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error